We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 13, 2020

Efficacy and Safety of Lorlatinib via Early- or Expanded-Access Programs in TKI-Refractory ALK+ or ROS1+ NSCLC

Journal of Thoracic Oncology


Additional Info

Journal of Thoracic Oncology
An International Real-World Analysis of Efficacy and Safety of Lorlatinib via Early or Expanded Access Programs in Patients With TKI-Refractory ALK+ or ROS1+ NSCLC
J Thorac Oncol 2020 Apr 28;[EPub Ahead of Print], VW Zhu, Y-T Lin, D-W Kim, et al

Further Reading